IDS and mucopolysaccharidosis type 2: In the present study, all nine of the IDS mutations were consistent with the clinical phenotypes of the human subjects from the MPS newborn screening programs in Taiwan, therefore, we believe this platform can be used as an important reference for medical professionals to assess the prognosis of MPS II subjects with different IDS mutations, and to provide them with the most timely and appropriate treatment at early disease stages.